The zevalin market research report is one of a series of new reports that provides zevalin market statistics, including the zevalin industry global market size, regional shares, competitors with the zevalin market share, detailed zevalin market segments, market trends, and opportunities, and any further data you may need to thrive in the zevalin industry. This zevalin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising prevalence of cancers, growth in healthcare infrastructure, increasing emphasis on early diagnosis, rising demand for outpatient treatment options, and increasing government support for cancer treatment initiatives. Major trends in the forecast period include advances in radioimmunotherapy, development of more precise drug delivery systems, radiolabeled antibody development, nuclear medicine innovation, and artificial intelligence in drug discovery.
The increasing incidence of non-Hodgkin’s lymphoma is expected to significantly drive the growth of the Zevalin market. Non-Hodgkin lymphoma refers to a group of blood cancers that begin in lymphocytes and affect both the lymphatic and immune systems. Several factors contribute to the rise in non-Hodgkin lymphoma cases, including an aging population, higher exposure to risk factors such as immunosuppression, environmental influences, and lifestyle changes. Zevalin is a monoclonal antibody designed to target CD20, a protein found on B-cells, which are commonly affected by non-Hodgkin’s lymphoma. The therapy delivers targeted radiation to destroy cancerous B-cells, helping shrink tumors and increasing the chances of remission. For example, in January 2024, the American Cancer Society reported that non-Hodgkin lymphoma is one of the most common cancers in the U.S., accounting for around 4% of all new cancer cases. Approximately 80,620 new diagnoses are expected in 2024, including 44,590 males and 36,030 females. As a result, the rising incidence of this lymphoma is boosting the demand for Zevalin.
The expansion of healthcare infrastructure is another key factor propelling the growth of the Zevalin market. Healthcare infrastructure includes the systems, facilities, equipment, and workforce that support healthcare delivery. The improvement in healthcare infrastructure is driven by various factors such as an aging population, increased demand for quality healthcare services, government investment, and technological advancements in medicine. As healthcare infrastructure continues to grow, it enhances access to advanced cancer treatments such as Zevalin, which plays a critical role in treating cancer and improving patient outcomes. For instance, in May 2023, the American Health Care Association reported that the number of hospitals in the U.S. had increased to 6,129, reflecting a growth of 0.591% from the previous year. Thus, the strengthening of healthcare infrastructure is contributing to the rise of the Zevalin market.
The growing geriatric population is set to further drive the growth of the Zevalin market. The geriatric population, consisting of individuals aged 65 and older, often requires specialized medical care due to age-related health issues. This increase in the elderly population is mainly due to higher life expectancy, reduced fertility rates, and better healthcare access. Zevalin provides a targeted and less invasive treatment, making it particularly suitable for older patients who may have other underlying health conditions. It minimizes side effects and improves treatment outcomes, thus enhancing the quality of life for elderly patients. For instance, in July 2024, the House of Commons Library in the UK reported that for every 100 individuals aged 20 to 64, there are about 33 individuals aged 65 and over. In 2022, there were 12.7 million people aged 65 or older, making up 19% of the population, with projections indicating this figure will rise to 22.1 million by 2072, or 27% of the population. As the geriatric population increases, so does the demand for Zevalin as a treatment option.
The key company operating in the zevalin market is Acrotech Biopharma Inc.
North America was the largest region in the zevalin market in 2024. The regions covered in zevalin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zevalin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zevalin (ibritumomab tiuxetan) is a monoclonal antibody used to treat non-Hodgkin lymphoma. It is a radiolabeled therapy that combines an antibody with yttrium-90, a radioactive substance, to target and destroy cancer cells. This targeted radiation helps slow lymphoma growth while minimizing damage to healthy tissues.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zevalin are relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) and previously untreated follicular non-Hodgkin lymphoma (NHL). Relapsed or refractory low-grade NHL refers to cases where the disease has either returned after initial treatment (relapsed) or is resistant to further therapy (refractory). Zevalin is available in various formulations, such as In-111 Zevalin and Y-90 Zevalin, and is distributed through multiple channels, including hospitals, specialty pharmacies, and online pharmacies. It is used by a range of patients, including adults and the elderly.
The zevalin market consists of sales of injections, radiolabeled therapy kits, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising prevalence of cancers, growth in healthcare infrastructure, increasing emphasis on early diagnosis, rising demand for outpatient treatment options, and increasing government support for cancer treatment initiatives. Major trends in the forecast period include advances in radioimmunotherapy, development of more precise drug delivery systems, radiolabeled antibody development, nuclear medicine innovation, and artificial intelligence in drug discovery.
The increasing incidence of non-Hodgkin’s lymphoma is expected to significantly drive the growth of the Zevalin market. Non-Hodgkin lymphoma refers to a group of blood cancers that begin in lymphocytes and affect both the lymphatic and immune systems. Several factors contribute to the rise in non-Hodgkin lymphoma cases, including an aging population, higher exposure to risk factors such as immunosuppression, environmental influences, and lifestyle changes. Zevalin is a monoclonal antibody designed to target CD20, a protein found on B-cells, which are commonly affected by non-Hodgkin’s lymphoma. The therapy delivers targeted radiation to destroy cancerous B-cells, helping shrink tumors and increasing the chances of remission. For example, in January 2024, the American Cancer Society reported that non-Hodgkin lymphoma is one of the most common cancers in the U.S., accounting for around 4% of all new cancer cases. Approximately 80,620 new diagnoses are expected in 2024, including 44,590 males and 36,030 females. As a result, the rising incidence of this lymphoma is boosting the demand for Zevalin.
The expansion of healthcare infrastructure is another key factor propelling the growth of the Zevalin market. Healthcare infrastructure includes the systems, facilities, equipment, and workforce that support healthcare delivery. The improvement in healthcare infrastructure is driven by various factors such as an aging population, increased demand for quality healthcare services, government investment, and technological advancements in medicine. As healthcare infrastructure continues to grow, it enhances access to advanced cancer treatments such as Zevalin, which plays a critical role in treating cancer and improving patient outcomes. For instance, in May 2023, the American Health Care Association reported that the number of hospitals in the U.S. had increased to 6,129, reflecting a growth of 0.591% from the previous year. Thus, the strengthening of healthcare infrastructure is contributing to the rise of the Zevalin market.
The growing geriatric population is set to further drive the growth of the Zevalin market. The geriatric population, consisting of individuals aged 65 and older, often requires specialized medical care due to age-related health issues. This increase in the elderly population is mainly due to higher life expectancy, reduced fertility rates, and better healthcare access. Zevalin provides a targeted and less invasive treatment, making it particularly suitable for older patients who may have other underlying health conditions. It minimizes side effects and improves treatment outcomes, thus enhancing the quality of life for elderly patients. For instance, in July 2024, the House of Commons Library in the UK reported that for every 100 individuals aged 20 to 64, there are about 33 individuals aged 65 and over. In 2022, there were 12.7 million people aged 65 or older, making up 19% of the population, with projections indicating this figure will rise to 22.1 million by 2072, or 27% of the population. As the geriatric population increases, so does the demand for Zevalin as a treatment option.
The key company operating in the zevalin market is Acrotech Biopharma Inc.
North America was the largest region in the zevalin market in 2024. The regions covered in zevalin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zevalin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zevalin (ibritumomab tiuxetan) is a monoclonal antibody used to treat non-Hodgkin lymphoma. It is a radiolabeled therapy that combines an antibody with yttrium-90, a radioactive substance, to target and destroy cancer cells. This targeted radiation helps slow lymphoma growth while minimizing damage to healthy tissues.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zevalin are relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) and previously untreated follicular non-Hodgkin lymphoma (NHL). Relapsed or refractory low-grade NHL refers to cases where the disease has either returned after initial treatment (relapsed) or is resistant to further therapy (refractory). Zevalin is available in various formulations, such as In-111 Zevalin and Y-90 Zevalin, and is distributed through multiple channels, including hospitals, specialty pharmacies, and online pharmacies. It is used by a range of patients, including adults and the elderly.
The zevalin market consists of sales of injections, radiolabeled therapy kits, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Zevalin Market Characteristics4. Zevalin Market Trends And Strategies5. Zevalin Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Zevalin Pricing Analysis & Forecasts30. Global Zevalin Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Zevalin Market32. Recent Developments In The Zevalin Market
3. Zevalin Market Biologic Drug Characteristics
6. Global Zevalin Growth Analysis And Strategic Analysis Framework
8. Zevalin Market Segmentation
9. Global Zevalin Epidemiology Of Clinical Indications
10. Zevalin Market Regional And Country Analysis
11. Asia-Pacific Zevalin Market
12. China Zevalin Market
13. India Zevalin Market
14. Japan Zevalin Market
15. Australia Zevalin Market
16. South Korea Zevalin Market
17. Western Europe Zevalin Market
18. UK Zevalin Market
19. Germany Zevalin Market
20. France Zevalin Market
21. Eastern Europe Zevalin Market
22. North America Zevalin Market
23. USA Zevalin Market
24. Canada Zevalin Market
25. South America Zevalin Market
26. Middle East Zevalin Market
27. Africa Zevalin Market
28. Zevalin Market Competitive Landscape And Company Profiles
29. Global Zevalin Market Pipeline Analysis
33. Zevalin Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Zevalin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on zevalin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for zevalin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The zevalin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Relapsed Or Refractory Low-Grade Non-Hodgkin Lymphoma (NHL); Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)2) By Formulation: In-111 Zevalin; Y-90 Zevalin
3) By Distribution Channel: Hospitals; Specialty Pharmacies; Online Pharmacies
4) By End-User: Adult Patients; Geriatric Patients
Key Companies Profiled: Acrotech Biopharma Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Acrotech Biopharma Inc.
